Metabolic Solutions Development Co.
Metabolic Solutions Development Co. LLC announced that Jerry Colca, co-founder and chief scientific officer of MSDC, presented results of a Phase 2a study at the 14th International Conference on Alzheimer’s Drug Discovery.
Metabolic Solutions Development Co. LLC announced Wednesday the publication of data in the latest issue of the scientific journal PLOS ONE on a new drug target for treating type 2 diabetes by boosting the body’s sensitivity to insulin.
Breakthrough research by Metabolic Solutions Development Co., including data published Wednesday on a new drug target for type 2 diabetes, underscores the key role a quality life sciences incubator can play, according to southwest Michigan life science leaders.
A study published online in the Journal of Biological Chemistry showed a new drug to treat diabetes being developed by Metabolic Solutions Development Co. LLC, MSDC-0602, improved insulin resistance and inflammation in obese mice.
Kalamazoo-based Metabolic Solutions Development Co. and collaborators will present their research providing insights into the therapeutic potential of increasing brown adipose (fat) tissue in the treatment of diabetes and the unique mechanism of action of the […]
Kalamazoo-based Metabolic Solutions Development Co., a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced Tuesday that it has launched a Phase 2a trial for MSDC-0602, the company’s second drug candidate for the treatment of type 2 diabetes.
A Kalamazoo pharma startup has a drug candidate that may offer better treatment for diseases related to obesity, including diabetes. Metabolic Solutions Development Co. will present research at the European Association for the Study of […]